Core Viewpoint - PROCEPT BioRobotics Corporation is set to report its financial results for Q2 2025 on August 6, 2025, with a conference call scheduled for the same day [1]. Company Overview - PROCEPT BioRobotics focuses on advancing patient care in urology through innovative surgical robotics solutions [1]. - The company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3]. - Aquablation therapy is designed to provide effective and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), regardless of prostate size or surgeon experience [3]. - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3]. - The company has established a robust clinical foundation with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3].
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025